Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
United States
Site 5112, David Geffen School of Medicine at UCLA, Los Angeles, California Site 5052, University of Colorado Denver, Aurora, Colorado Site 5051, University of Florida Jacksonville, Jacksonville, Florida Site 5127, Pediatric Perinatal HIV, Miami, Florida Site 5030, Emory University School of Medicine, Atlanta, Georgia Site 5083, Rush University Cook County Hospital Chicago, Chicago, Illinois Site 5092, Johns Hopkins University Baltimore, Baltimore, Maryland Site 5114, Bronx-Lebanon Hospital Center, The Bronx, New York Site 5013, Jacobi Medical Center Bronx, The Bronx, New York Site 6501, St. Jude Children's Research Hospital, Memphis, Tennessee Site 5128, Baylor College of Medicine/Texas Children's Hospital, Houston, Texas Brazil
Site 5072, Hospital Federal dos Servidores do Estado, Rio de Janeiro Site 5097, Hospital Geral De Nova Iguacu Brazil, Rio de Janeiro Kenya
Site 5121, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center, Kericho, Kericho Puerto Rico
Site 5129, IMPAACT/Gamma Project/UPR Pediatric HIV/AIDS Research, San Juan South Africa
Site 8950, FAMCRU, Cape Town, Parrow Valley Zimbabwe
Site 31890, Harare Family Care, Harare